Nucleos(t)ide analogue (NA) monotherapy remains the dominant therapeutic approach for adult chronic hepatitis B in India, accounting for the largest share of the 2029 market. NAs such as tenofovir disoproxil fumarate, tenofovir alafenamide, and entecavir provide high viral suppression rates with a favorable safety profile, enabling long‑term outpatient management. The extensive prescribing footprint is driven by national treatment guidelines that prioritize NAs as first‑line agents, the relative affordability of generic formulations, and the expanding screening programs that increase diagnosed patient pools. Consequently, NA monotherapy contributes roughly 55 % of the total market value, reflecting both volume and price dynamics. Its prevalence also influences supply chain logistics, reimbursement negotiations, and R&D focus, as manufacturers target incremental improvements in resistance barriers and dosing convenience. The segment’s stability underpins market forecasts, while emerging resistance patterns may prompt modest shifts toward newer agents toward the end of the forecast horizon. Additionally, patient adherence programs and tele‑medicine follow‑up have reinforced its market penetration.
